Zurcher Kantonalbank (Zurich Cantonalbank) Tcr2 Therapeutics Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

  • $28 Billion
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 21, 2022
SELL
$2.4 - $4.71 $4,272 - $8,383
-1,780 Closed
0 $0
Q4 2021

Feb 01, 2022
SELL
$4.58 - $8.34 $12,379 - $22,543
-2,703 Reduced 60.29%
1,780 $8,000
Q3 2021

Nov 15, 2021
BUY
$8.44 - $18.35 $8 - $18
1 Added 0.02%
4,483 $38,000
Q2 2021

Jul 30, 2021
BUY
$16.41 - $24.71 $2,822 - $4,250
172 Added 3.99%
4,482 $74,000
Q1 2021

May 03, 2021
BUY
$20.38 - $34.07 $87,837 - $146,841
4,310 New
4,310 $95,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email